Literature DB >> 18258238

VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis.

Takaaki Fujii1, Yoshikazu Yonemitsu, Mitsuho Onimaru, Makoto Inoue, Mamoru Hasegawa, Hiroyuki Kuwano, Katsuo Sueishi.   

Abstract

Vascular endothelial growth factor (VEGF) is a major positive angiogenic factor. Using a murine hindlimb ischemia model, we previously showed that fibroblast growth factor-2 (FGF-2) enhances the expression of endogenous VEGF which highly contribute to the therapeutic effect of FGF-2 gene transfer. Recently, placental growth factor (PlGF) has been shown to play an important role in angiogenesis. However, the molecular mechanism of endogenous PlGF during FGF-2-mediated angiogenesis has not been elucidated. Severe hindlimb ischemia stimulated PlGF expression that was more strongly enhanced by FGF-2 gene transfer, and a blockade of PlGF activity diminished the recovery of blood flow by FGF-2-mediated angiogenesis. The PlGF expression in cultured endothelial cells was significantly enhanced by VEGF stimulation, but not by FGF-2. The upregulation of endogenous PlGF expression was significantly decreased by the inhibition of endogenous VEGF activity in vivo. Subsequent signal inhibition experiments revealed that the PKC, MEK, and possibly NF-kappaB-related pathways were essential in stimulating PlGF expression with VEGF, while p70S6K is the regulator for VEGF expression. These results indicate that the FGF-2-mediated enhancement of PlGF expression was dependent on VEGF function, and the FGF-2/VEGF axis participates in FGF-2-mediated angiogenesis indirectly via PlGF as well as directly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258238     DOI: 10.1016/j.atherosclerosis.2007.12.012

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  17 in total

1.  Placenta growth factor and vascular endothelial growth factor a have differential, cell-type specific patterns of expression in vascular cells.

Authors:  Lingjin Xiang; Rohan Varshney; Nabil A Rashdan; Jennifer H Shaw; Pamela G Lloyd
Journal:  Microcirculation       Date:  2014-07       Impact factor: 2.628

2.  Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation.

Authors:  B Ferraro; Y L Cruz; M Baldwin; D Coppola; R Heller
Journal:  Gene Ther       Date:  2010-04-15       Impact factor: 5.250

3.  Regulation of the expression balance of angiopoietin-1 and angiopoietin-2 by Shh and FGF-2.

Authors:  Takaaki Fujii; Hiroyuki Kuwano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-01-29       Impact factor: 2.416

4.  Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration.

Authors:  Ji Hyung Chung; Eun Kyoung Im; Tae Won Jin; Seung-Min Lee; Soo Hyuk Kim; Eun Young Choi; Min-Jeong Shin; Kyung Hye Lee; Yangsoo Jang
Journal:  Exp Mol Med       Date:  2011-04-30       Impact factor: 8.718

5.  Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression.

Authors:  Takaaki Fujii; Reina Yajima; Hironori Tatsuki; Katuya Oosone; Hiroyuki Kuwano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-10-01       Impact factor: 2.416

6.  Site-specific connexin phosphorylation is associated with reduced heterocellular communication between smooth muscle and endothelium.

Authors:  Adam C Straub; Scott R Johnstone; Katherine R Heberlein; Michael J Rizzo; Angela K Best; Scott Boitano; Brant E Isakson
Journal:  J Vasc Res       Date:  2009-12-16       Impact factor: 1.934

Review 7.  PlGF: a multitasking cytokine with disease-restricted activity.

Authors:  Mieke Dewerchin; Peter Carmeliet
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

8.  Macrophage β2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis.

Authors:  Jiange Zhang; Yasha Modi; Timur Yarovinsky; Jun Yu; Mark Collinge; Themis Kyriakides; Yizhun Zhu; William C Sessa; Ruggero Pardi; Jeffrey R Bender
Journal:  Am J Pathol       Date:  2012-02-07       Impact factor: 4.307

9.  Adequate Selection of a Therapeutic Site Enables Efficient Development of Collateral Vessels in Angiogenic Treatment With Bone Marrow Mononuclear Cells.

Authors:  Masaru Nemoto; Hiroyuki Koyama; Ayako Nishiyama; Kunihiro Shigematsu; Tetsuro Miyata; Toshiaki Watanabe
Journal:  J Am Heart Assoc       Date:  2015-09-14       Impact factor: 5.501

10.  VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.

Authors:  Takaaki Fujii; Tomoko Hirakata; Sasagu Kurozumi; Shoko Tokuda; Yuko Nakazawa; Sayaka Obayashi; Reina Yajima; Tetsunari Oyama; Ken Shirabe
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.